NCT07208370

Outcomes of Gillian Barrie Syn

Outcome Predictors of Gillian Barrie Syndrome In Pediatrics

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Assiut University · Academic / Other
• Sex: All
• Age: 1 Month – 18 Years
• Healthy volunteers: Not accepted

Summary

This study analyze clinical and biological factors influencing disease course and outcome. Some research identified factors like disease severity, sensory symptoms, and autonomic instability as indicators of poor outcome. Ongoing research aims to develop accurate predictive models for improved treatment and care.

Detailed description

Guillain-Barré Syndrome (GBS) is the most common cause of acute flaccid paralysis in children worldwide, often presenting with progressive weakness, areflexia, and varying degrees of autonomic and cranial nerve involvement. It is an immune-mediated disorder, commonly triggered by preceding infections such as Campylobacter jejuni, cytomegalovirus, or Epstein-Barr virus. Pediatric patients generally have a better prognosis than adults, yet a significant proportion still suffer from residual weakness or prolonged recovery. Understanding early predictors of outcome is essential for optimizing treatment and counseling families.\[1\]\[2\] Several clinical and laboratory factors have been identified as potential predictors of poor outcomes in pediatric GBS. These include rapid progression to peak weakness, requirement of mechanical ventilation, presence of cranial nerve involvement (especially bulbar palsy), autonomic dysfunction, and the axonal subtypes of GBS on nerve conduction studies. Early identification of such factors allows for more aggressive supportive care and closer monitoring.\[3\]\[4\]\[5\] Electrophysiological classification also plays a vital role in predicting outcomes. Children with acute motor axonal neuropathy (AMAN) and acute motor-sensory axonal neuropathy (AMSAN) tend to have a slower and less complete recovery compared to those with acute inflammatory demyelinating polyneuropathy (AIDP). Furthermore, delayed initiation of immunotherapy such as intravenous immunoglobulin (IVIG) or plasma exchange may be associated with poorer prognosis.\[6\]\[7\] Biomarkers like elevated cerebrospinal fluid (CSF) protein without pleocytosis (albuminocytologic dissociation) are typical in GBS but do not necessarily predict outcome. However, higher CSF protein levels in the early phase may correlate with more severe disease. Some recent studies have also suggested that MRI enhancement of spinal nerve roots may be associated with disease severity, although its prognostic value remains under investigation.\[8\]\[9\] In conclusion, recognizing early outcome predictors in pediatric GBS is crucial for timely intervention, resource allocation, and family support. Although many children recover fully, identifying those at risk for complications can improve both short- and long-term care strategies.\[2\]\[3\]\[10\]

Conditions

• Outcome of Gillian Barrie

Interventions

Type	Name	Description
OTHER	clinical assessment	standraized clinical evaluation to assess disease sevirity and progration

Timeline

• Start date: 2025-10-01
• Primary completion: 2026-10-01
• Completion: 2026-12-01
• First posted: 2025-10-06
• Last updated: 2025-10-06

Locations

1 site across 1 country: Egypt